Dhan Chand: Honored to have presented at the Global Cancer Movement Conference
Dhan Chand, Vice President of Research at Agenus, reshared a post on LinkedIn by OncoDaily, adding:
“Honored to have presented at the Global Cancer Movement Conference, where I discussed botensilimab and its promising potential in colorectal cancer treatment.
Special thanks to OncoDaily for sharing my presentation and making it freely accessible to all on YouTube.
Together, we’re challenging conventional thinking and working toward better outcomes for patients.”
Quoting OncoDaily’s post:
“Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers
Botensilimab is poised to revolutionize the treatment of MSS colorectal cancer, offering promising results and a new hope for patients with limited options.”
Dhan Chand, Ph.D., is Vice President of Research at Agenus, focusing on cancer immunology, immunotherapy, and cell and molecular biology. Previously, he served as a Graduate Research Assistant and Project Co-Leader in the Department of Cell and Systems Biology at the University of Toronto
Furter Reading:
Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer – Day 1
Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer – Day 2
Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer – Day 3
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023